26.05.2005 07:00:00
|
PURE. NATURAL. LONG LASTING. PURAGEN DERMAL FILLER LAUNCHED TODAY; Next-generation hyaluronic acid product - the benchmark in consumer cosmetic choices
PURAGEN is based on hyaluronic acid, a natural skin componentresponsible for the plumpness and smoothness typical of younger skin.The source of the new product's performance lies in its innovativestructure - only in PURAGEN are hyaluronic acid molecules doublecross-linked to one another. This strengthened bonding providespatients with two key benefits:
-- the gel particles are smaller making the procedure more comfortable
-- the gel particles are designed to survive longer before being absorbed by the skin
"Puragen represents an important advancement for patients andgives a very smooth injection, resulting in a uniform filling to thelips and lower face lines," commented Nicholas Lowe, M.D., a leadingdermatologist and cosmetic surgeon with practices in London, England,and Santa Monica, California. "My European patients are pleased withthe results of the product thus far, which appears to provide a longduration of wrinkle correction."
PURAGEN is a pure form of hyaluronic acid derived from bacterialfermentation and does not have the risks associated with otherproducts derived from animal by-products. PURAGEN is uniquelystabilised through Mentor's patent-protected DXL(TM) technology, whichintroduces two discrete double cross-linking reactions designed toprovide improved product stability relative to all other commerciallyavailable hyaluronic acid based dermal fillers on the market inEurope, Canada and the United States.
About Mentor Corporation
Founded in 1969, Mentor Corporation is a leading supplier ofmedical products for the global healthcare market. The Companydevelops, manufactures and markets innovative, science-based productsfor the aesthetics, urologic specialties and clinical and consumerhealthcare markets around the world. The Company's website iswww.mentorcorp.com
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
29.01.25 |
Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: Hätte sich ein Investment in Johnson Johnson vor 5 Jahren inzwischen rentiert? (finanzen.at) | |
28.01.25 |
Dienstagshandel in New York: Dow Jones schlussendlich in Grün (finanzen.at) | |
28.01.25 |
NYSE-Handel: Dow Jones verbucht Zuschläge (finanzen.at) | |
28.01.25 |
Freundlicher Handel: Dow Jones am Mittag mit Gewinnen (finanzen.at) | |
27.01.25 |
NYSE-Handel: Dow Jones schlussendlich freundlich (finanzen.at) | |
27.01.25 |
Dow Jones aktuell: Dow Jones mit positivem Vorzeichen (finanzen.at) | |
27.01.25 |
NYSE-Handel: Dow Jones-Börsianer greifen am Montagmittag zu (finanzen.at) | |
27.01.25 |
Angespannte Stimmung in New York: Dow Jones notiert zum Handelsstart im Minus (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 147,14 | 0,12% |
Indizes in diesem Artikel
S&P 600 SmallCap | 935,46 | -0,94% |